General
Preferred name
PIDOTIMOD
Synonyms
Pidotomod ()
NSC-759841 ()
Pilimod ()
P&D ID
PD001689
CAS
121808-62-6
Tags
available
drug
Drug Status
approved
investigational
Max Phase
2.0
Drug indication
Neoplasm
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al[1][2].
DESCRIPTION Pidotimod is a synthetic dipeptide with immunomodulatory properties. (TargetMol Bioactive Compound Library)
Compound Sets
15
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
244.05
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
0
cLogP
-0.75
TPSA
86.71
Fraction CSP3
0.67
Chiral centers
2.0
Largest ring
5.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Bacterial
Immunostimulant
Immunology & Inflammation related
MOA
interferon receptor agonist, interleukin receptor agonist
Indication
immune adjuvant
Pathway
Anti-infection
Microbiology/virology
Source data